Piramal Pharma Solutions expands its peptide API plant in Turbhe with a new Band-5 containment spray drying unit
Executive summary: Piramal Pharma Solutions installed a new spray drying system with Band-5 containment at its peptide API site in Turbhe, India. The addition enables the production of highly potent peptide APIs that require strict containment, expanding the company's service offering in the growing peptide therapeutics market.
Who is involved: Piramal Pharma Solutions (the contracting CDMO), its engineering team, and the equipment supplier that provided the spray drying unit.
Likely next: The unit is expected to commence validation and commercial production in the second half of 2026, supporting new peptide drug projects.
Piramal Pharma Solutions has added a spray drying line equipped with its own ventilation, nitrogen supply and control systems to its specialized peptide API facility in Turbhe, India. The unit provides Band-5 containment, which is required for handling highly potent peptide active pharmaceutical ingredients. The expansion increases the company's capacity to manufacture potent peptides for contract development and manufacturing clients.
Timeline
- — Piramal Pharma Solutions erweitert Peptid-API-Anlage um moderne Sprühtrocknungsanlage (PR Newswire)
Analysis — what this means
Sectors affected
- peptide active pharmaceutical ingredients (API) manufacturing
- contract development and manufacturing organization (CDMO) services for peptide therapeutics
- highly potent compound containment solutions
Regulatory implications
- Meets Band-5 containment standards required for highly potent peptides under EU GMP and FDA guidelines
- Facilitates compliance with occupational exposure limits for potent APIs
Sources
Related cases
- API International launches NSF/ANSI/CAN 61 and 372 certified stainless steel flanges for sanitary process applications
- Piramal Pharma Solutions expands peptide API capacity with a new Class 5 spray‑drying unit in Turbhe, India
- Open-weight AI models are shifting competitive advantage from licensing proprietary models to enterprises that can best integrate and run these free, compressed models on their own infrastructure
- Middle East tensions and a sharp API crude draw push Brent prices back toward $88, reversing Tuesday's losses
- Asymchem’s Dunhua facility secures FDA clearance for continuous API manufacturing, marking a milestone for carbapenem production in China